GS 840: Began U.K. Phase I/II double-blind, placebo-controlled, randomized trial of once-daily oral dosing for four weeks, to evaluate safety and anti-viral act

Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS 840, oral prodrug of GS 393 (PMEA) nucleotide analog Indication: Chronic hepatitis B Status: Began U.K. Phase I/II double-blind, placebo-...